Sub Category
Study Name
B-52: A Randomized Phase III Trial Evaluating Pathologic Complete Response Rates in Patients with Hormone Receptor-Positive, HER2,- Positive, Large Operable and Locally Advanced Breast Cancer Treated with Neoadjuvant Therapy of Docetaxel, Carboplatin, Trastuzumab, Pertuzumab (TCHP) With or Without Estrogen Deprivation
Principal Investigator
Gordan Srkalovic MD, PhD
Study Information
Contact for Questions
Sparrow Cancer Center 800-968-5570

Site view: at a glance